PIK3CA Alterations in NSCLC: Clinical Characteristics of a “Neglected” Population of Oncogene-Addicted Patients
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background/Objectives: Alterations of the phosphatidylinositol 3-kinase catalytic subunit alpha gene (PIK3CA) are identified in approximately 2–4% of non-small cell lung cancer (NSCLC) cases; however, their biological and clinical relevance in NSCLC remains incompletely understood. This study aimed to comprehensively characterize the clinical and molecular features, as well as outcomes, of patients with PIK3CA-altered NSCLC across different disease stages. Methods: We conducted a retrospective multicenter analysis of 62 patients with histologically confirmed early-stage or advanced NSCLC-harboring PIK3CA alterations (mutations and/or gene amplifications) treated between 2015 and 2022 at three Italian institutions. Demographic, clinical, pathological, and molecular variables were systematically collected and analyzed. Results: PIK3CA mutations accounted for the majority of alterations (90.3%), while amplifications represented 9.7%. The most frequent mutations involved exon 9 (66.1%), predominantly E545K and E542K, followed by exon 20 (16.1%). Most patients were current or former smokers, and concomitant oncogenic alterations were detected in 59.7% of cases, most commonly KRAS mutations. A history of prior malignancy was reported in 24.6% of cases. In the metastatic setting, adenocarcinoma histology was associated with significantly longer overall survival (OS) compared with non-adenocarcinoma histologies (18.4 vs. 5.5 months; p = 0.02). Patients with PD-L1–negative tumors demonstrated a numerically longer OS than those with PD-L1–positive tumors; however, this difference did not reach statistical significance (19.1 vs. 5.4 months; p = 0.05). No statistically significant survival differences were observed according to specific PIK3CA mutation subtypes or treatment strategies. Conclusions: PIK3CA-altered NSCLC represents a molecularly heterogeneous and clinically understudied subgroup, frequently characterized by co-occurring oncogenic alterations. In this study, no definitive prognostic or predictive role for PIK3CA alterations could be established. Nevertheless, these findings provide a descriptive real-world characterization of this molecular subset and support the need for validation in larger, prospectively designed, molecularly stratified studies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- PIK3CA Alterations in NSCLC: Clinical Characteristics of a “Neglected” Population of Oncogene-Addicted Patients
- Date Crossref
- 04/02/2026
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
IRCCS Humanitas Research Hospital Medical Oncology and Hematology Unit pays non établi dans la noticeÉtablissement de santé
-
ASST Melegnano e della Martesana pays non établi dans la noticeÉtablissement de santé
-
Humanitas University Department of Biomedical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Agostino Gemelli University Polyclinic pays non établi dans la noticeÉtablissement de santé
-
Ospedale Sacro Cuore Don Calabria pays non établi dans la noticeÉtablissement de santé
-
Vizzolo Predabissi Hospital Division of Oncology pays non établi dans la noticeÉtablissement de santé
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS U.O.C. Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Sacro Cuore Don Calabria Hospital (IRCCS) Department of Oncology pays non établi dans la noticeÉtablissement de santé
Medical Oncology and Hematology Unit — IRCCS Humanitas Research Hospital, ASST Melegnano e della Martesana et Department of Biomedical Sciences — Humanitas University, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.